Viagra - After one year

Urology

Volumn 54, Issue 1, 1999, Pages 12-17

  Steers, William D ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; NITRATE; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; SILDENAFIL;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DYSPEPSIA; ERECTILE DYSFUNCTION; HEADACHE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NOSE CONGESTION; ORAL DRUG ADMINISTRATION; PATIENT SATISFACTION; PRIAPISM; PRIORITY JOURNAL; REVIEW; STROKE;

EID: 0033168276     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00133-8     Document Type: Short Survey

References (42)

1. Ballard SA, Gingell CJ, Tang K, et al: Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 159: 2164-2171, 1998.
2. Moreland RB, Goldstein I, and Traish A: Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life Sci 62: L309-L318, 1998.
3. Chuang A, Strauss J, Steers WD, et al: Nitric oxide and cGMP mediate corpus cavernosum smooth muscle relaxation and erection by affecting cross-bridge function. Life Sci 63: 185-194, 1998.
4. Chuang AT, Strauss J, Murphy R, et al: Effects of sildenafil (Viagra), a type 5 cGMP phosphodiesterase inhibitor on cyclic GMP, myosin light chain phosphorylation and isometric force in the rabbit corpus cavernosum in vitro. J Urol 160: 257-261, 1998.
5. Jeremy JY, Ballard SA, Naylor AM, et al: Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 79: 958-963, 1997.
6. Stief CG, Uckert S, Becker AJ, et al: The effect of the specific phosphodiesterase (PDE) inhibitors on human and rabbit cavernous tissue in vitro and in vivo. J Urol 159: 1390-1393, 1998.
7. Carter AJ, Ballard SA, and Naylor AM: Effect of the selective phosphodiesterase type 5 inhibitor sildenafil on erectile function in the anesthetized dog. J Urol 160: 242-246, 1998.
8. Andersson K-E, Gemalmaz H, Chapman T, et al: The effect of sildenafil on apomorphine evoked increases in intra-cavernous pressure in the awake rat. J Urol 161: 1707-1712, 1999.
9. Loughney K, Hill TR, Florio VA, et al: Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase. Gene 216: 139-147, 1998.
10. Melis MR, and Ariolas A: Role of central nitric oxide in the control of penile erection and yawning. Prog Neuropsy-chopharmacol Biol Psychiatry 21: 899-922, 1999.
11. Muirhead AM, Pearson JG, Rance D, et al: Pharmacoki-netics of sildenafil: a selective cyclic guanosine monophosphate specific phosphodiesterase type 5 inhibitor after single oral doses in fasted and fed healthy volunteers. Br J Pharmacol 42: 268P, 1996.
12. Eardley I, Brooks J, Yates P, et al: Sildenafil: an oral therapy for erectile dysfunction with efficacy at least 4 hours duration (abstract). Int J Impot Res (in press).
13. Goldstein I, Lue TF, Padma-Nathan H, et al: Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 338: 1397-1404, 1998.
14. Abel P, Hodges M, Hargreaves C, et al: Sildenafil an oral treatment for erectile dysfunction: a 12 week, double blind placebo-controlled study. Int J Impot Res (in press).
15. Padma-Nathan H, Steers WD, and Wicker PA: Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction - a double-blind, placebo-controlled study of 329 patients. Int J Clin Prac 52: 375-379, 1998.
16. Hartman U, Eric JH, Cuzin B, et al: Sildenafil (Viagra): analysis of preferred doses in a European, 6-month, double-blind placebo-controlled, flexible dose escalation study in patients with erectile dysfunction (abstract). Int J Impot Res (in press).
17. Feldman HA: Sildenafil in the treatment of erectile dysfunction: efficacy in patients taking concomitant antihypertensive therapy. Am J Hypertens (in press).
18. Price D: Sildenafil efficacy in the treatment of erectile dysfunction in patients with common concomitant conditions (abstract). Int J Impot Res (in press).
19. Shabsigh R: Efficacy of sildenafil is not affected by etiology of erectile dysfunction (abstract). Int J Impot Res (in press).
20. Hultling C: Partners' perceptions of efficacy of sildenafil (Viagra) in the treatment of erectile dysfunction (abstract). Int J Impot Res (in press).
21. Gingell C, BuvatJ,Jardin A, et al: Sildenafil (Viagra), an oral treatment for erectile dysfunction: 1-year, open label, extension studies (abstract). Int J Impot Res (in press).
22. Osterloh I, Collins M, Wicker P, et al: Sildenafil: overall safety profile in 18 double blind, placebo-controlled, clinical trials of erectile dysfunction (abstract). Int J Impot Res (in press).
23. Tm) in the treatment of erectile dysfunction. Int J Impot Res 10: 69-73, 1998.
24. Auerbach S: The overall safety profile of sildenafil, an effective and well-tolerated oral treatment for erectile dysfunction (ED) of broad spectrum etiology. J Am Geriatr Soc (in press).
25. Boolell M, Gepiattee S, Gingell JC, et al: Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 78: 257-261, 1996.
26. Steers WD: Meta-analysis of the efficacy of sildenafil in the treatment of severe erectile dysfunction. J Urol 159(suppl): 238, 1998.
27. Zippe CD, Kedia AW, Kedia K, et al: Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). Urology 52: 963-966, 1998.
28. Derry FA, Dinsmore WW, Fraser M, et al: Efficacy and safety of oral sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury. Neurology 51: 1629-1633, 1998.
29. Price DE, Gingell JC, Gepiattee S, et al: Sildenafil - study of a novel oral treatment for erectile dysfunction in diabetic men. Diabet Med 15: 821-825, 1998.
30. Marks LS, Duda C, Dorey FJ, et al: Treatment of erectile dysfunction with sildenafil. Urology 53: 19-24, 1999.
31. Fava M, Rankin MA, Alpert JE, et al: An open trial of oral sildenafil in antidepressant-induced sexual dysfunction. Psychother Psychosom 67: 328-331, 1998.
32. Feenstra J, Vandriepierik RM, Lacle CF, et al: Acute myocardial infarction associated with sildenafil. Lancet 352: 957-958, 1998.
33. Lopez-Lazaro L, Garcia-Arenillas M, Portoles-Perez A, et al: Acute myocardial infarction associated with sildenafil. Lancet 352: 1936-1937, 1998.
34. Greenstein A, Chen J, Miller H, et al: Correlation of coronary artery occlusion at angiography and erectile dysfunction. Int J Impot Res 9: 123-126, 1997.
35. El-Sakka AT, and Lue TF: Does a heart attack mean the end of sexual life? Am Coll Cardiol Educ Highlights Winter: 6-10, 1996.
36. Muller JE, Mittleman MA, Maclure M, et al: Triggering myocardial infarction by sexual activity. JAMA 275: 1405-1409, 1996.
37. Cheitlin MD, Hutter AM, Brindus RG, et al: Use of sildenafil (Viagra) in patients with cardiovascular disease. J Am Coll Cardiol 33: 273-282, 1998.
38. Donahue SP, and Taylor RJ: Pupil-sparing third nerve palsy associated with sildenafil citrate (Viagra). Am J Ophthalmol 126: 476-477, 1998.
39. Porst H: The potential for sildenafil for salvage therapy in severe male impotence (abstract). Int J Impot Res (in press).
40. Montorsi F, Guazzoni G, Strambi LF, et al: Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol 158: 1408-1410, 1997.
41. Park K, Moreland RB, Goldstein I, et al: Sildenafil inhibits phosphodiesterase type 5 in human clitoral corpus cavernosum smooth muscle. Biochem Biophys Res Commun 249: 612-617, 1998.
42. Meuleman EJ: Presented at Pharmacologic Management of Sexual Dysfunction Meeting, Los Angeles, October 9-10, 1998.